Tenofovir Disoproxil Market Report 2025

The tenofovir disoproxil market size has grown steadily in recent years. It will grow from $3.58 billion in 2024 to $3.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to the growth in awareness and early detection of viral infections, rising cases of hepatitis b infections, expansion of generic drug manufacturing for tenofovir disoproxil, rising number of clinical trials supporting tenofovir efficacy, and growth in healthcare funding for infectious disease treatment.

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the rising demand for long-acting tenofovir formulations, increasing focus on combination therapies with newer antivirals, rising regulatory approvals for novel tenofovir combinations, rising focus on pediatric formulations of tenofovir, and increasing demand for tenofovir in post-exposure prophylaxis. Major trends in the forecast period include development of novel drug delivery systems, integration of artificial intelligence in drug development, advancements in combination therapies, advancements in nanotechnology-based delivery, and advancements in fixed-dose combination therapies.

The forecast of 5.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers may hamper U.S. HIV clinics by inflating prices of nucleotide reverse transcriptase inhibitors and pre-exposure prophylaxis and post-exposure prophylaxis formulations manufactured in India and Ireland, elevating HIV prevention and treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of HIV and AIDS is expected to drive the growth of the tenofovir disoproxil market. HIV and AIDS are chronic viral infections that weaken the immune system by attacking CD4 cells, making the body more susceptible to infections and diseases. The rising prevalence of these conditions is attributed to factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and the emergence of drug-resistant virus strains. The growing number of HIV and AIDS cases is increasing the demand for tenofovir disoproxil, a key antiretroviral drug used for treatment and prevention. For example, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, reported that by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections recorded that year. Additionally, in 2022, around 630,000 deaths from AIDS-related illnesses occurred globally, with the number of people living with HIV rising to 39.9 million (36.1 million-44.6 million) in 2023. As a result, the increasing prevalence of HIV and AIDS is fueling the growth of the tenofovir disoproxil market.

The growing prevalence of hepatitis B is also expected to contribute to the expansion of the tenofovir disoproxil market. Hepatitis B is a viral infection that targets the liver and can lead to both acute and chronic disease, transmitted through contact with infected blood or bodily fluids. Factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations are driving the rise in hepatitis B cases. Tenofovir disoproxil is a widely used treatment for chronic hepatitis B, helping to suppress viral replication and minimize liver damage. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, estimated that between 580,000 and 2.4 million people in the United States are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Consequently, the increasing prevalence of hepatitis B is contributing to the demand for tenofovir disoproxil.

Leading companies in the tenofovir disoproxil market are focusing on innovative formulations, such as combination therapies, to enhance HIV/AIDS treatment and maintain a competitive edge. Combination therapy involves the simultaneous use of two or more treatments to improve therapeutic outcomes and patient well-being. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease. The FDA’s approval was based on data from a Phase II clinical trial demonstrating the drug’s safety and efficacy in children as young as six years old.

Major players in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd.

North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tenofovir disoproxil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The tenofovir disoproxil market research report is one of a series of new reports that provides tenofovir disoproxil market statistics, including the tenofovir disoproxil industry's global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Tenofovir disoproxil is a medication used for treating HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it converts into its active form in the body, inhibiting viral replication. It belongs to the nucleotide reverse transcriptase inhibitors (NRTIs) class, which blocks a crucial enzyme required for viral multiplication.

The primary forms of tenofovir disoproxil are tablets and powder. Tablets are solid medicinal forms designed for easy swallowing, dissolving in the digestive system to release the active ingredient either gradually or immediately. The medication is distributed through online pharmacies, retail pharmacies, and wholesalers or distributors, with applications primarily in hospitals and clinics.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.